These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 8582120)

  • 1. Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update.
    Morgan DJ; McLean AJ
    Clin Pharmacokinet; 1995 Nov; 29(5):370-91. PubMed ID: 8582120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacokinetics in patients with liver disease.
    McLean AJ; Morgan DJ
    Clin Pharmacokinet; 1991 Jul; 21(1):42-69. PubMed ID: 1914341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction.
    Verbeeck RK
    Eur J Clin Pharmacol; 2008 Dec; 64(12):1147-61. PubMed ID: 18762933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of hepatic insufficiency on pharmacokinetics and drug dosing.
    Verbeeck RK; Horsmans Y
    Pharm World Sci; 1998 Oct; 20(5):183-92. PubMed ID: 9820880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacokinetics of newer antibacterial agents in liver disease.
    Westphal JF; Brogard JM
    Clin Pharmacokinet; 1993 Jan; 24(1):46-58. PubMed ID: 8448972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Principles and clinical application of assessing alterations in renal elimination pathways.
    Tett SE; Kirkpatrick CM; Gross AS; McLachlan AJ
    Clin Pharmacokinet; 2003; 42(14):1193-211. PubMed ID: 14606929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic disease and drug pharmacokinetics.
    Williams RL; Mamelok RD
    Clin Pharmacokinet; 1980; 5(6):528-47. PubMed ID: 7002418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analgesics in patients with hepatic impairment: pharmacology and clinical implications.
    Bosilkovska M; Walder B; Besson M; Daali Y; Desmeules J
    Drugs; 2012 Aug; 72(12):1645-69. PubMed ID: 22867045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose adjustment in patients with liver disease.
    Delcò F; Tchambaz L; Schlienger R; Drewe J; Krähenbühl S
    Drug Saf; 2005; 28(6):529-45. PubMed ID: 15924505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function.
    Welink J; Boven E; Vermorken JB; Gall HE; van der Vijgh WJ
    Clin Cancer Res; 1999 Sep; 5(9):2349-58. PubMed ID: 10499604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic drug interactions in liver disease: An update.
    Palatini P; De Martin S
    World J Gastroenterol; 2016 Jan; 22(3):1260-78. PubMed ID: 26811663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiarrhythmics: elimination and dosage considerations in hepatic impairment.
    Klotz U
    Clin Pharmacokinet; 2007; 46(12):985-96. PubMed ID: 18027986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic basis for the safety of glimepiride in risk groups of NIDDM patients.
    Rosenkranz B
    Horm Metab Res; 1996 Sep; 28(9):434-9. PubMed ID: 8911979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of chronic renal failure on the disposition of highly hepatically metabolized drugs.
    Yuan R; Venitz J
    Int J Clin Pharmacol Ther; 2000 May; 38(5):245-53. PubMed ID: 10839468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock.
    De Paepe P; Belpaire FM; Buylaert WA
    Clin Pharmacokinet; 2002; 41(14):1135-51. PubMed ID: 12405864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Mechanism of action of xipamide and its classification as a "low ceiling diuretic". Pharmacodynamic-pharmacokinetic studies in healthy volunteers and in kidney and liver patients].
    Knauf H; Mutschler E
    Arzneimittelforschung; 2005; 55(1):1-14. PubMed ID: 15727159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic metabolism of paclitaxel and its impact in patients with altered hepatic function.
    Panday VR; Huizing MT; Willemse PH; De Graeff A; ten Bokkel Huinink WW; Vermorken JB; Beijnen JH
    Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-34-S11-38. PubMed ID: 9314297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of Hepatic Impairment and Implications for Pharmacokinetics of Substance Use Treatment.
    Talal AH; Venuto CS; Younis I
    Clin Pharmacol Drug Dev; 2017 Mar; 6(2):206-212. PubMed ID: 28263464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ontogeny of hepatic and renal systemic clearance pathways in infants: part I.
    Alcorn J; McNamara PJ
    Clin Pharmacokinet; 2002; 41(12):959-98. PubMed ID: 12222995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
    Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
    Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.